Candle Therapeutics secured $100M not through equity, but by selling a percentage of future US sales of its Phase III cancer therapy. This non-dilutive royalty financing provides capital for a product launch without giving up ownership, a strategic option for companies nearing FDA approval.
Companies like Turbine, which raised $25M, are attracting investment for AI platforms that create "virtual cell models." These in silico simulations predict cellular responses to treatments, aiming to accelerate discovery and improve the clinical translation of immunology and oncology drugs, representing a shift from screening to predictive biology.
Gilead's acquisition of Arcellx includes a CVR, promising an extra $5 per share if the drug anita-cel hits a $6B sales target by 2029. This structure mitigates upfront risk for Gilead while allowing Arcellx shareholders to benefit from future commercial success, aligning incentives post-acquisition.
Recent Phase III results show that missing a primary endpoint isn't a death sentence. Gossamer Bio is in FDA discussions after its PAH drug missed a statistical threshold, while Novo Nordisk plans a new, higher-dose trial for its obesity drug after it failed to show non-inferiority against a competitor. This highlights strategic resilience in late-stage development.